1. Diabetic Retinopathy Alan D. Letson, MD Professor & William H. Havener Chair in Ophthalmology Department of Ophthalmology Alan.Letson@osumc.edu Part I: Introduction and The History of Treatment for Diabetic Retinopathy

2. Learning Objectives  Primary Learning Objective: Apply knowledge of risk factors and retinal findings to screening and management of diabetic retinopathy  Secondary Learning Objectives:  differentiate the lesions of non-proliferative and proliferative retinopathy  describe screening, diagnosis and management of the various causes of vision loss related to diabetic retinopathy

3. Acknowledgment  Several of the slides used in this presentation come from slide sets prepared for diabetes education by:  Pennsylvania Diabetes Association  American Academy of Ophthalmology

4. Why are we talking about this specific ophthalmic disease?  Diabetic Retinopathy is the most common cause of blindness  Diabetic Retinopathy is a “model” for many other retinal vascular diseases  Ocular lesions and complications seen in Diabetic Retinopathy are not unique to Diabetes, and can be seen as a result of many other systemic vascular diseases such as hypertension, vaso-occlusive diseases, and collagen-vascular diseases.  The treatments used for DR are the same as treatments for many other retinal vascular diseases.  Non-ophthalmologists can play an important role in the screening and detection of retinopathy and can help their patients by making sure they benefit from early detection and treatment.  Non-ophthalmologists are key players in the treatment of diabetic eye disease by knowing about and managing the medical risks that contribute to this disease.

5. Prior to 1974  No known effective treatments  Blindness common outcome  Pituitary ablation

6. 1976 Diabetic Retinopathy Study  Demonstrated effectiveness of pan retinal photocoagulation (PRP) for proliferative retinopathy

7. Late 1970’s – Early 1980’s  Refinement of laser procedures  Development of vitreo-retinal microsurgical instrumentation and procedures

8. 1982: Early Treatment Diabetic Retinopathy Study  Demonstrated effectiveness of focal photocoagulation for macular edema.

9. 2005 – to date  First use of VEGF inhibitors in 2005  Pharmaceutical Industry Sponsored Trials  August 2012 ranibizumab (Lucentis) became FDA approved for treating Diabetic macular Edema  2014 – DRCR.net trial comparing aflibercept to ranibizumab showed superiority of aflibercept.

10. Currently  Diabetic Retinopathy remains one of the most significant complications of diabetes and continues to be the leading cause of blindness.

11.  Early detection and early treatment are crucial for the prevention of blindness Diabetic Retinopathy

12. Alan D. Letson MD Professor & William H Havener Chair in Ophthalmology Department of Ophthalmology Alan.Letson@osumc.edu Part 2: Risk Factors and Lesions

13. A 66 year old woman presents with decreased vision in her right eye. What additional information is important? What will you do to evaluate and manage her complaint?

14. A 35 year man, 25 year Hx of IDDM, previously visually asymptomatic with 20/20 vision, now presents with a sudden onset of floaters

15. 58 year old woman CC: gradual blur of vision, getting worse for 6 months PMH: NIDDM 11 years, HgbA1C = 8.7 BP 158/90 Va: 20/80 OD, 20/25 OS

16. Who Gets Retinopathy?  Factors include  Age of onset  Duration of disease  Degree of control  Hypertension

17. Prevalence of Retinopathy Duration of Diabetes (years) 100 75 50 25 0 0 5 10 15 20 %

18. Prior to Age 30  Duration less than 5 years  17% have some retinopathy  Macular edema unusual, PDR rare  Duration greater than 15 years  98% have some retinopathy  Approximately 1/3 have macular edema  Approximately 1/3 have PDR Age of Onset and Duration

19. After Age 30  Duration less than 5 years  29% have some retinopathy.  Macular edema unusual, PDR 2%  Duration greater than 5 years  78% have some retinopathy  Approximately 28% have macular edema  Approximately 16% have PDR

20. DCCT and UKPS  Intense glucose control reduced rates of progression of retinopathy  Blood Pressure control reduced progression of retinopathy

22. Diabetes Control and Complications Trial  Intensive glucose control  No baseline retinopathy  76% reduction in the risk of developing significant retinopathy

23. Diabetes Control and Complications Trial  Intensive glucose control  Mild to moderate retinopathy  54% reduction in progression  47% reduction in development of severe NPDR or PDR  56% reduction in need for laser surgery.

24. Hypertension and Diabetes  There is a positive correlation between elevated systolic blood pressure and the development of exudative complications of retinopathy

26. Pathophysiology Known  Hyperglycemia > loss of pericytes  Loss of pericytes > loss of capillary endothelia and capillaries  Loss of capillaries > hypoxia and ischemia  Hypoxia > release of VEGF

27. Pathophysiology Known  VEG-F  Stimulates proliferation of new vessels  Increases vascular permeability  Has pro-inflammatory action

28. Other Possible Mechanisms  Aldose reductase: glucose to sorbitol causing osmotic cell damage  Protein Kinase C with VEGF upregulation, enhanced by hyperglycemia  Reactive oxygen species causes oxidative damage – increased VEGF  Growth hormone plays permissive role for VEGF, reduction in GH prevents neovascularization

29. Classification and Lesions of Diabetic Retinopathy  NonProliferative Diabetic Retinopathy (NPDR)  Proliferative Diabetic Retinopathy (PDR)

30. Early NonProliferative Diabetic Retinopathy  Microaneurysms  Hard exudates  Intraretinal hemorrhages  Macular edema*

33. Advanced NonProliferative Diabetic Retinopathy  Cotton wool spots  IntraRetinal Microvascular Abnomalities (IRMA)  Venous Beading

35. Courtesy PDA

36. Advanced NonProliferative Diabetic Retinopathy  High risk of imminent PDR  No immediate treatment  Patient needs re-evaluated in 2-4 months

39. Proliferative Diabetic Retinopathy  Signs of NPDR including macular edema  Neovascularization of disc (NVD) or retina (NVE)  Vitreous hemorrhage  Fibrous proliferation with retinal detachment

40. Courtesy PDA

47. Diabetic Retinopathy Alan D. Letson MD Professor & William H Havener Chair in Ophthalmology Department of Ophthalmology Alan.Letson@osumc.edu Part 3: Vision loss in Diabetic Retinopathy and how do we treat it?

48. What Causes Vision Loss?  Maculopathy can occur in NPDR or PDR  Vitreous hemorrhage PDR  Traction Retinal Detachment PDR

49. Diabetic Maculopathy Includes  Macular edema (retinal swelling)  Lipid exudation (hard exudates)  Ischemia (capillary nonperfusion)

50. What Are Symptoms of Maculopathy?  None  Gradual progressive loss of central vision  Vision is “smeared”, “oily”, “filmy”, “scum”, “dirty glasses”  Central scotoma

51. When is Maculopathy Treated?  Retinal edema within 1/3 disc diameter from the center of the fovea  Hard exudate within 1/3 DD associated with edema  Edema greater than 1 DD in area within 1 dd from fovea

52. How do We Treat Macular Edema?  Treatment guided by Fluorescein angiography  Focal laser coagulation of microaneurysms  Anti-VEGF drugs

56. Video 1 Video 2

58. Results of Treatment for Macular Edema  50% reduction in rate of vision loss  20% improved vision  60% stable vision  20% will show progressive vision loss in spite of treatment

59. AntiVEGF Treatment for Diabetic Macular Edema  RIDE study 2007-2012: Ranibizumab safe and effective for DME  FDA approval August 2012  DRCR.net: laser plus Ranibizumab superior to laser alone or ranibizumab alone for DME  DRCR.net ( OSU is a member) aflibercept superior to ranibizumab 2014

60. What are Symptoms of Proliferative Diabetic Retinopathy?  None  Floaters and cobwebs  Rapid dramatic vision loss  Visual field loss

62. When is Proliferative Diabetic Retinopathy Treated?  Pan Retinal Photocoagulation for High Risk PDR:  NVD  NVD or NVE with preretinal bleeding  Vitrectomy for non-clearing vitreous hemorrhage or TRD

63. Pan Retinal Photocoagulation (PRP)  Outpatient procedure  1000-2000 laser burns  1 to 3 sessions  Side effects:  Decreased night vision  Decreased peripheral vision  Decreased central vision

64. Courtesy PDA

67. Fiberoptic illumination Fiberoptic illumination Infusion Line Infusion Line Suction/ Cutting tip Suction/ Cutting tip AAO

69. Results of Treatment for Proliferative Diabetic Retinopathy  Laser reduces risk of severe vision loss by 60%  Vitrectomy restores pre-hemorrhage vision in 85% and allows completion of treatment with laser  Vitrectomy restores vision in 65% for repair of TRD

71. Diabetic Retinopathy Alan D. Letson MD Professor & William H Havener Chair in Ophthalmology Department of Ophthalmology Alan.Letson@osumc.edu Part 4: The Role of the Non Ophthalmologist

72. Medical Management: Hgb A1C < 7.0  Good Glucose control  Both DCCT and UK study show reduction in ocular complications.

73. Medical Management: Hypertension  A significant risk factor for development and progression of retinopathy.  Systolic < 130 mmHg  Risk reduction similar for ACE inhibitors or other agents (Beta-blockers)

74. Medical Management: Lipid Abnormality  Increased retinal exudation with:  Elevated serum cholesterol  Elevated triglycerides  Manage lipid abnormalities

75. Medical Management: Anemia  Frequently overlooked  Significant effects on retina  Hgb < 12gms = 2x risk for retinopathy  Increased risk of macular edema.

76. Medical Management: Anemia  Low hematocrit is an independent risk factor for developing PDR and severe vision loss.  Frequently related to renal disease and associated lack of erythropoeitin production.  Correction reduces retinal exudation and edema.

77. Medical Management: Medication FAQs  Aspirin – no increase in severity or frequency of hemorrhage  ASA did decrease death from Cardiovascular disease by 17%  Anti-oxidants - ? Benefit of Vitamins C, E, beta-carotene

78. Medical Management: When to refer?  Situations requiring referral:  Macular edema  NVD/NVE  Vitreous bleeding  Sudden unexplained vision loss

79. Medical Management: Screening Criteria  Pregnancy: discussion risk before conception  Existing retinopathy may worsen  Retinopathy may develop  Retinal evaluation before conception or in first trimester.

80. Medical Management: Screening Criteria  Diabetes Dx < age 30:  Annual ophthalmologic exams beginning 5 years after diagnosis.  Ophthalmoscopy by PCP at other intervals.

81. Medical Management: Screening Criteria  Diabetes Dx > age 30:  Annual ophthalmologic exams beginning at the time of diagnosis.  Ophthalmoscopy by PCP for signs at other intervals.

82. Final Comment  Team Event: patient, ophthalmologist and physician managing diabetes.  With good team play, the prognosis for maintaining functional sight is good.

84. Summary  describe the risk factors for developing diabetic retinopathy  describe the lesions of non-proliferative retinopathy  describe the lesions of proliferative retinopathy  classify the stages of diabetic retinopathy  describe the indications and options for ophthalmic treatment of non-proliferative retinopathy  describe the indications and options for treatment of proliferative retinopathy  describe the medical management of persons with diabetes that will impact retinopathy  list screening criteria for ophthalmic examination in person with diabetes

85. Thank you for completing this module Questions? Contact me at: Alan.Letson@osumc.edu

86. Survey We would appreciate your feedback on this module. Click on the button below to complete a brief survey. Your responses and comments will be shared with the module’s author, the LSI EdTech team, and LSI curriculum leaders. We will use your feedback to improve future versions of the module. The survey is both optional and anonymous and should take less than 5 minutes to complete. Survey